GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Mainak BanerjeeRimesh PalSatinath MukhopadhyayKirthana Nair

Published in: The Journal of clinical endocrinology and metabolism (2023)

GLP-1RAs, precisely longer acting formulations, reduced ischemic cerebrovascular events in T2DM. Observed benefits were significantly higher in patients with shorter T2DM duration and higher eGFR.

Keyphrases

glycemic control
type diabetes
small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
cardiovascular disease
insulin resistance
emergency department
ischemia reperfusion injury
weight loss
wild type
metabolic syndrome
oxidative stress
blood brain barrier
brain injury
subarachnoid hemorrhage